Azenta, Inc.
PublicAzenta, Inc. is now publicly traded
The data on this page reflects Azenta, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Buyout/LBO
Feb 1, 2022
Est. Valuation at Exit
$3B
Total Funding Raised
$3B
Company Overview
Azenta, Inc. is a biotechnology company that provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies.
AI Layer
Non-AI
Keywords
sample managementautomated sample storagelab automationbiorepository servicesgenomic servicescryogenic storageLIMSgene sequencinglife science toolscold chain logisticsmultiomics servicesNGSnext-generation sequencingbiobankinggene synthesislaboratory information management systemlab consumablesSanger sequencing
Azenta, Inc. Comparables
Compare Azenta, Inc. with similar companies based on industry and business-model similarity.
Azenta, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Buyout/LBO | Feb 1, 2022 |
Azenta, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Thomas H. Lee Partners | Buyout/LBO |
Azenta, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
Headquarters—
Employee Range1,246
Year Founded1978
Last FundingFeb 1, 2022